Advances in Immune Monitoring Series

The spectrum of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative diseases (B-CLPD) encompasses defects primarily in antibody production and hypogammaglobulinemia, alongside varying T cell and innate immunity defects. Like primary immunodeficiency disorders (PID), a classification system is warranted to categorize SID defects and assess infection risk.

Despite similarities in infection profiles between PID and SID to B-CLPD, it is of utmost importance to rule out PID at B-CLPD diagnosis, which has clinical and prognostic implications for the patients and their families. An integrated approach that incorporates immunological biomarkers alongside traditional prognostic indicators is essential for enhancing diagnostic accuracy and tailoring risk-adapted therapies in patients with B-CLPD and concurrent immune dysfunction. Collaboration between hematologists and immunologists is imperative for navigating the complex landscape of immune dysfunction in cancer.

Join us to learn:
 

• The clinical relevance of an adequate assessment and classification of the immunodeficiency in B-CLPD in predicting disease progression and guiding treatment decisions.
• The challenges in diagnosing primary versus secondary immunodeficiency and the importance of early recognition.
• Through exploration of the genomic landscape of B-CLPD and its intersection with PID, potential shared pathways and therapeutic targets are underscored, highlighting the relevance of interdisciplinary collaboration and integrated approaches to patient care.